Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rottenberg

Showing results (651-660 of 684) with videos related to

Pageof 69
Sort By:
Molecular Cell|January 18, 2016
HELB Is a Feedback Inhibitor of DNA End ResectionJán Tkáč, Guotai Xu, Hemanta Adhikary, et al.
BJU International|June 19, 2013
Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate DiagnosticsTimur H Kuru, Karan Wadhwa, Richard Tsung Meng Chang, et al.
Cancer Research|July 16, 2010
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistanceNatalia Issaeva, Huw D Thomas, Tatjana Djureinovic, et al.
Cell Reports|August 27, 2020
Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End JoiningPaola Francica, Merve Mutlu, Vincent A Blomen, et al.
Cell Reports|May 17, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsMarco Barazas, Stefano Annunziato, Stephen J Pettitt, et al.
Molecular Cell|September 23, 2021
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gapsMariana Paes Dias, Vivek Tripathi, Ingrid van der Heijden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
NPJ Precision Oncology|January 10, 2024
Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomicsAlberto Valdeolivas, Bettina Amberg, Nicolas Giroud, et al.
Cancer Research|March 8, 2012
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumorsSven Rottenberg, Marieke A Vollebergh, Bas de Hoon, et al.
Nature Cell Biology|June 2, 2026
Nucleophagy removes cytotoxic trapped PARP1Gwendoline Hoslett, Sara Tribble, Pauline Lascaux, et al.
Pageof 69

Showing results (651-660 of 684) with videos related to

Sort By:
Pageof 69
Molecular Cell|January 18, 2016
HELB Is a Feedback Inhibitor of DNA End ResectionJán Tkáč, Guotai Xu, Hemanta Adhikary, et al.
BJU International|June 19, 2013
Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate DiagnosticsTimur H Kuru, Karan Wadhwa, Richard Tsung Meng Chang, et al.
Cancer Research|July 16, 2010
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistanceNatalia Issaeva, Huw D Thomas, Tatjana Djureinovic, et al.
Cell Reports|August 27, 2020
Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End JoiningPaola Francica, Merve Mutlu, Vincent A Blomen, et al.
Cell Reports|May 17, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsMarco Barazas, Stefano Annunziato, Stephen J Pettitt, et al.
Molecular Cell|September 23, 2021
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gapsMariana Paes Dias, Vivek Tripathi, Ingrid van der Heijden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
NPJ Precision Oncology|January 10, 2024
Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomicsAlberto Valdeolivas, Bettina Amberg, Nicolas Giroud, et al.
Cancer Research|March 8, 2012
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumorsSven Rottenberg, Marieke A Vollebergh, Bas de Hoon, et al.
Nature Cell Biology|June 2, 2026
Nucleophagy removes cytotoxic trapped PARP1Gwendoline Hoslett, Sara Tribble, Pauline Lascaux, et al.
Pageof 69